Alec Stranahan
Stock Analyst at B of A Securities
(0.62)
# 3,919
Out of 4,896 analysts
30
Total ratings
33.33%
Success rate
-27.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $21.16 | +98.49% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.36 | +175.23% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $5.81 | +158.18% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.79 | +268.19% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.63 | +574.85% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.45 | +244.83% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.98 | +50.75% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.88 | +420.83% | 1 | Aug 8, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $38.04 | +44.58% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $6.84 | +163.16% | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $140 | $148.17 | -5.51% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.83 | +375.65% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $37.09 | -83.82% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.19 | +320.17% | 1 | Dec 2, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $21.16
Upside: +98.49%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.36
Upside: +175.23%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.81
Upside: +158.18%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.79
Upside: +268.19%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.63
Upside: +574.85%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.45
Upside: +244.83%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.98
Upside: +50.75%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.88
Upside: +420.83%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $38.04
Upside: +44.58%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $6.84
Upside: +163.16%
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $148.17
Upside: -5.51%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.83
Upside: +375.65%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $37.09
Upside: -83.82%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.19
Upside: +320.17%